Copenhagen, Denmark, April 19, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces the implementation of long-term incentive programs for 2026 (the "LTIP") for the Board of Directors, Corporate Management and employees of Zealand Pharma, in accordance with the Company's remuneration policy and overall guidelines for incentive pay, as adopted at the annual general meeting held on ...